NIOX Group Updates Total Voting Rights After Employee Option Exercises

An announcement from Circassia Pharmaceuticals ( (GB:NIOX) ) is now available.

NIOX Group has confirmed that its issued share capital stands at 417,939,265 ordinary shares, each carrying one voting right, with no shares held in treasury. This updated total follows the exercise of 4,937 share options by employees, with the resulting new shares admitted via existing block listings and ranking pari passu with the rest of the stock.

The revised share count provides the new denominator for investors assessing whether their holdings trigger disclosure thresholds under UK transparency rules. While the change in capital is minimal in scale, it ensures regulatory clarity on voting rights and share base, supporting accurate reporting by shareholders and maintaining compliance with FCA disclosure requirements.

The most recent analyst rating on (GB:NIOX) stock is a Buy with a £86.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.

Spark’s Take on GB:NIOX Stock

According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Neutral.

Circassia Pharmaceuticals’ overall stock score is driven by its strong financial performance and positive corporate events, which are offset by neutral technical indicators and a high P/E ratio suggesting overvaluation. The company’s robust cash flow and low leverage provide a stable foundation, while recent corporate actions signal confidence in future growth.

To see Spark’s full report on GB:NIOX stock, click here.

More about Circassia Pharmaceuticals

NIOX Group plc is a UK-listed healthcare company on AIM, focused on respiratory diagnostics. The group develops and supplies medical devices and technologies used to support the management and monitoring of respiratory conditions, positioning itself within the broader life sciences and medtech sector.

Average Trading Volume: 968,169

Technical Sentiment Signal: Sell

Current Market Cap: £264.1M

See more data about NIOX stock on TipRanks’ Stock Analysis page.